Plant-made pharmaceuticals: An overview and update by Davies, H. Maelor
59
Plant-Made Pharmaceuticals: 
An Overview and Update
H. Maelor Davies
University	of	Kentucky
Lexington,	KY
The development of plant genetic transformation in the early 980s introduced the pos-
sibility of having plants express non-native (“foreign”) genes, and thereby accumulate 
non-native proteins in their cells and tissues. Thus the concept of “plant molecular farm-
ing” was born, envisaging crop plants as production “vehicles” for useful and/or valuable 
proteins that originally derived from microbial or animal sources. Several advantages 
were claimed for such plant-based production, relative to bulk production of the natural 
source for the corresponding protein, including overall economy of production, lack of 
need for major capital investment (e.g. in fermentation bioreactors), ease and economy 
of scale-up, lack of risk of contamination with human pathogens, etc. (For a background 
overview of plant molecular farming, see Collins and Shepherd, 99). Because the case for 
using plants as the production system became more compelling as the yield of protein per 
plant increased, proprietary gene-expression technologies were developed specifically for 
achieving very high concentrations of “foreign” proteins in plant tissues. These technolo-
gies, in turn, resulted in the emergence of several agricultural biotechnology companies 
specializing in plant molecular farming. A wide variety of proteins were expressed in a 
number of plant species, illustrating the potential of the approach to supply products for 
pharmaceutical, industrial-enzyme, structural-polymer, etc., markets. Clinical trials in 
humans were conducted, successfully, with protein pharmaceuticals generated in plants 
(e.g. Ma et	al., 998). A particularly attractive feature of the plant molecular farming 
concept, which was apparent from its outset, is its potential to provide opportunities for 
both the agricultural sector and the biotechnology business sector simultaneously.
A variant on the molecular farming theme, which developed contemporarily with it, 
is the concept of “edible vaccines.” In this strategy, the entire plant tissue or organ (such 
as a fruit) in which the protein pharmaceutical accumulates is also the final delivery 
device for the protein product, and no extraction of the protein from the plant material 
0 Agricultural Biotechnology: Beyond Food and Energy to Health and the Environment
is necessary. Edible vaccines are considered elsewhere in this conference, and will not be 
discussed further here.
In contrast with the spectacular scientific progress in “proving” the principle, however, 
the development of significant markets for plant-manufactured proteins failed to hap-
pen, so that by the mid-990s the plant molecular farming field was essentially stalled. 
The companies that were based on appropriate gene-expression technologies were in a 
survival-oriented mode rather than in a state of vibrant growth, and little was happen-
ing in terms of further technology enhancements. Most troubling was the sense that the 
end-users of the technology, i.e. those companies who owned protein pharmaceuticals, 
enzymes and other possible product “targets” for plant-based production, appeared to 
be unconvinced regarding the plant manufacturing platform. Field-level production had 
been demonstrated on a pilot scale, and some post-harvest bioprocessing capability was 
constructed. But, in spite of these advances towards scaled-up commercial applications, 
the plant molecular farming biotechnology sector continue to lack much-needed en-
dorsement by significant clients whose protein medicinals and protein reagents addressed 
substantial and sustainable markets. The plant-based production “platform” was, in effect, 
a technology searching for an application.
Fortunately, much has changed in the last 5 years or so, largely as a result of biotechnol-
ogy’s increasing impact on drug development. The fledgling molecular farming industry 
is ideally placed to address the resulting demand for protein pharmaceuticals, and con-
sequently has re-characterized its technology platform as “plant-made pharmaceuticals” 
(PMPs). Applications to other proteins such as industrial enzymes, now referred to as 
“plant-made industrial products,” are seen as a future priority.
This brief overview will consider the current status of the PMP industry and the chal-
lenges facing large-scale implementation of the PMP opportunity today. Using some of 
our own research at Kentucky tobacco research and Development Center (KtrDC) as 
an example, I will also discuss the interface between the PMP industry and conventional 
crop agriculture. This is an aspect that has often been neglected in the past, but one that 
comes sharply into focus when one recalls that conventional crops are not optimized for 
these new applications and that today’s regulatory, containment considerations render 
them even less suitable. rather than providing new plant varieties and corresponding 
new markets for production through existing crop agriculture—as was at one time en-
visaged—it now seems much more likely that a new, specialized crop agriculture will be 
constructed specifically to service the PMP opportunity.
It	now	seems	much	more	likely	that	a	new,	specialized	crop	
	agriculture	will	be	constructed	specifically	to	service	the	
PMP	opportunity.
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the PMP Opportunity today
to appreciate the current status of the PMP industry, we need to review both the capa-
bilities of the industry itself and the condition of the protein-pharmaceutical markets 
that it is designed to address. 
The basic philosophy of the PMP opportunity today can be stated in the following 
way:
• there is a substantial, and increasing, worldwide demand for protein pharmaceuti-
cals and therapeutics;
• existing and traditional methods of manufacturing proteins in bulk to the re-
quired level of purity and quality are stretched to capacity and will soon become 
limiting in protein-drug manufacturing;
• specialized plant-based gene-expression technologies are ready to provide an 
alternative manufacturing platform that can help meet the demand and thus over-
come the perceived “bottleneck” in protein production; and
• taken together, these situations make a strong case for commercial development 
of PMPs.
The following summary reviews each of the above aspects in relation to the current status 
of PMP commercialization.
Protein	Demand
The development of novel protein pharmaceuticals, vaccines, therapeutics and other 
medically useful molecules is an expected consequence of biotechnology-driven drug 
discovery. Accordingly, it is not surprising that proteins feature prominently in new drug 
development today, and that they are predicted to comprise a larger and larger propor-
tion of new medicines over the next decade or so. For example, an estimate of % of 
the pharmaceutical market as proteins in the year 000 is projected to expand to 0% 
by 00 (Price, 003). A 00 survey by the Pharmaceuticals research and Manufactur-
ers’ Association (http://www.phrma.org) indicated that 3 “biotech medicines” were 
in clinical trials or in advanced development (such as preparation for clinical trials) in 
the United States alone, in that year. Most of these prospective new drugs were proteins 
such as antibodies, enzymes, peptides, etc. Worldwide, many hundreds of monoclonal 
antibodies and other medicinally active proteins are in all stages of development from 
discovery through human trials. Moreover, some of these proteins will be administered 
in large amounts (e.g. mg/dose) that will necessitate large production volumes (Garber, 
00), and the prospect of personalized or individualized medicines for some products 
will pose particularly tough challenges for economical, custom, batch-wise production 
(e.g. Alison et	al., 003). Thus, the demand for pharmaceutical proteins is considerable, 
and growing, creating a market opportunity that was almost nonexistent when plant 
molecular farming was conceived in the 980s.
Protein-Manufacturing	Capacity
Next, let’s consider the extent to which this demand has created a supply-level crisis that 
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might stimulate the expansion of PMPs. An increasing demand for proteins creates oppor-
tunity for all possible production platforms, including the established way to manufacture 
proteins to the stringent standards laid down for veterinary and human applications, 
i.e. via fermentation of specialized microbial (bacteria and yeast) and mammalian (e.g. 
Chinese hamster ovary) cell lines, engineered to express the appropriate genes. We can, 
therefore, expect some expansion in this fermentation industry. While this will represent 
competition, the increasing need for proteins may also provide a chance for PMP tech-
nology not only to prove its fundamental capability but also to illustrate its efficiency in 
responding quickly, flexibly and perhaps economically to a rapidly evolving demand for 
product quantity and diversity.
Fermentation facilities require considerable capital investment and have finite capacity 
so that expansion also requires substantial capital. Such facilities are typically said to cost 
$300–$500 million to build, with a time frame of  to 5 years to cover construction, 
validation, and licensing (Thiel, 00). Not surprisingly, therefore, the initial surge of 
progress in protein drug development stressed existing fermentation capacity, raising seri-
ous concerns about a coming “capacity bottleneck.” As recently as 00, a representative 
from a contract manufacturing organization (CMO) in this field was quoted as saying 
(cited in Garber, 00):
…the	only	 long-term	solution	 is	 to	 shift	 some	production	(from	fermentation	
systems)	to	transgenic	animals	and	plants,	which	can	in	theory	be	scaled	up	much	
more	efficiently	to	virtually	any	level.
In our opinion at KtrDC, this period of “protein crisis” (Garber, 00) in the late 
990s and over the last few years generated considerable new interest in the PMP con-
cept. two more gene-expression technologies emerged as PMP companies during that 
time, and pharmaceutical companies began to examine the PMP-manufacturing option 
more seriously. The PMP industry and associated organizations (e.g. KtrDC and other 
PMP-relevant research programs) also became more recognizable as a biotechnology sec-
tor in its own right, featuring prominently in the Biotechnology Industry Organization 
(BIO; http://www.bio.org) and holding a biannual conference (Conference	on	Plant-Made	
Pharmaceuticals; http://archives.cpmp005.org).
The protein crisis might have become a forceful creator of new end-users and signifi-
cant markets for the PMP industry. However, sufficient expansion has taken place in 
the fermentation industry that the crisis appears to be over, at least for now. Indeed, the 
biomanufacturing news spotlight is now focused on the end of the capacity-expansion 
boom, and industry analysts opine that “…there is little immediate pressure for compa-
nies to move to alternative platforms (e.g. PMP) that are as yet commercially unproven” 
(Thiel, 00). Whereas just a few years earlier the transgenic animal- and plant-production 
systems were viewed with new interest as potential ways around the bottleneck, they are 
again left to make their own case for advantages, economy, etc., relative to the traditional 
methods of making proteins.
While it seems unlikely that there will be another sudden surge in demand for pro-
teins, the steady growth in demand will continue to apply pressure to the manufacturing 
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 industry. It will be interesting to see if the CMOs will repeatedly be able to raise financing 
for expansions, and whether the larger pharmaceutical companies that have their own 
protein products will invest further in fermentation capacity. Another possibility is that 
protein production will grow sufficiently as a business sector that it will become much 
more internally competitive, triggering new interest in more economical methods of 
production and hence, potentially, in PMPs.
PMP	Technologies
The need, once again, for the PMP industry to convince the pharmaceutical community 
that PMPs can become an established route of large-scale production, brings us conve-
niently to a short overview of PMP technologies, their capabilities, characteristics, strengths 
and weaknesses. table  lists the more prominently visible PMP companies, together with 
the kinds of gene-expression technologies on which they are based and the plant species 
with which they are compatible. The majority, if not all, of these proprietary technologies 
were derived originally from research conducted in the academic sector. The majority 
of them share an important attribute, namely the ability to drive protein accumulation 
in the appropriate plant tissue to very high enrichment levels relative to the native plant 
proteins in that tissue. Indeed, for a commercial PMP, an accumulation of product to 
a level of at least % of total soluble protein (tSP) by weight is considered necessary, 
with enrichments of 5–0% of tSP being preferable. With certain gene products that 
are particularly stable in the plant cell, and/or with certain technologies, enrichments 
approaching 80% of tSP may be attainable (e.g. Marillonnet et	al.,	00).
For	a	commercial	PMP,	an	accumulation	of	product	to	a	level	
of	at	least	1%	of	total	soluble	protein	by	weight	is	considered	
	necessary,	with	enrichments	of	5–10%	of	TSP	being	preferable.
Table 1. Some* exampleS of pmp companieS and TechnologieS
 Company name “Vehicle” plant Proprietary technology
 Large Scale Biology tobacco Viral transfection vector
 Icon Genetics tobacco Viral vector (and others)
 Chlorogen tobacco Chloroplast-based expression
 Planet Biotechnology tobacco Antibody production
 SemBioSys Safflower Oilseed-based expression
 Ventria Bioscience rice Seed-based expression
 Medicago Alfalfa Expression in forage crop
 Biolex Duckweed Expression in aquatic plant
*This is necessarily an incomplete list, on account of limited space and scope of this review article; omission of 
any company or technology does not imply any negative assessment or view.	
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While sharing a common feature of highly productive gene expression, the PMP tech-
nologies otherwise exhibit considerable diversity in regard to other characteristics and 
perceived advantages. Expression in stably transformed plants contrasts with expression 
through transfection with modified virus particles. Many of the expression technologies 
are restricted to certain plant species, but the overall list includes food/feed plants such 
as corn and canola, feed crops such as alfalfa, and non-food species such as tobacco and 
duckweed. Depending on the particular technology, expression may occur in the leaf and 
hence in the bulk of the plant’s above-ground biomass, or it may occur exclusively in seed 
or fruit tissues. Also, expression in the transgenic systems may be from vectors inserted 
in the nuclear genome or in the chloroplast genome. 
An in-depth comparative analysis of all these different PMP technologies is beyond 
the scope of this paper, but suffice it to say that each has particular advantages or unique 
features. Expression in the chloroplast, for example, may offer advantages in regard to 
containment and regulatory compliance when deployed in plants that exhibit little or 
no transfer of chloroplasts through pollen [for a review of chloroplast transformation, 
see Bogorad (000)]. Viral transfection systems (Lacomme et	al., 00; Marillonnet et	
al., 00) will pose different regulatory approval considerations from those required for 
transgenic plants, and this may be advantageous in some circumstances. Ease of post-
harvest isolation of the protein product, and subsequent bioprocessing is a unique claim 
made by an oilseed-based system (Moloney, 000). And at least one system is proven 
in the production of complex antibody molecules requiring simultaneous and balanced 
expression of several genes in the same plant cell (Wycoff, 005). Overall, this diversity of 
characteristics and features should work to the advantage of the PMP strategy, enabling 
it to address a wider range of product “targets” and production constraints (e.g. growing 
location, farming know-how, and special regulatory/containment considerations) than 
might be possible with only one or two gene-expression technologies.
The	PMP	industry	is	still	working	towards	its	first	truly	large-
scale	(100	acres	or	more),	preferably	ongoing,	provision	of	a	
protein	drug	to	a	client	company	or	to	consumers.
PMP	Engagement	of	Protein	Markets
The status of the PMP opportunity today is largely consistent with the ideal philosophy 
presented at the beginning of this section. Proteins represent an increasing proportion of 
pharmaceutical products, worldwide. While there is currently less concern about produc-
tion capacity for those proteins relative to the situation a few years ago, it seems possible 
that growth in markets for protein drugs, along with dosage and personalization issues, 
will continue to pose challenges for the capital-intensive, cell-culture-based manufactur-
ing platforms. The PMP platform comprises a range of impressive technologies with a 
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broad range of capabilities, ready to address these opportunities. But while there have 
been a few instances of commercial products’ being made via the PMP route, most have 
been small-scale (–00 acres), one-time, or experimental endeavors. to date, the PMP 
industry is still working towards its first truly large-scale (00 acres or more), preferably 
ongoing, provision of a protein drug to a client company or to consumers.
We will next examine the challenges that must be met for the industry to break through 
into such mainstream protein-drug manufacturing.
Challenges to PMP Development
The basic scientific and technical challenges of making “foreign” proteins in plants were 
met many years ago. And while it is true that plant-based production may not be feasible 
for some proteins [e.g. on account of different post-translational modifications such as 
glycosylation (Gomord et	al., 00)], and that technical advances continue to be made 
in expression levels and other aspects that may improve the range of products that can 
be made in plants, there is no shortage of viable PMP targets today. 
rather, the factors that most influence the growth rate of the industry at the present 
time are financial and business related. PMP companies must compete for the atten-
tion of investors who also review business models formed around other manufacturing 
platforms, and who may be more inclined to invest in companies that own the innova-
tive new protein drugs. (PMP companies sometimes own the product target as well as 
the production technology, but all seek to partner with companies who own additional 
prospective targets.)
This competition may become easier to beat once the PMP approach is embraced by 
the pharmaceutical industry as an established production platform. Factors that influence 
the pharmaceutical community’s acceptance of PMPs include the “cultural” differences 
between the pharmaceutical sector and the agricultural biotechnology sector, an overall 
lack of understanding of the economics of plant-based production (discussed further 
below), the lack of familiarity with large-scale purification of proteins from plants to 
the stringent specifications required for clinical application, and quite possibly a desire 
not to be the first drug company to adopt the PMP concept. to appreciate the cultural 
differences, one has only to contrast the highly controlled, highly contained, nature of 
bulk cell-culture systems in which every cell is almost identical to every other, with the 
PMP image of a greenhouse or a field of plants; it must be tempting for those engaged 
in protein-pharmaceutical manufacturing to persist with their established, long-proven, 
methods for reasons of familiarity and “comfort-level” alone.
If a protein-supply crisis does not drive a wider adoption of plant-based manufactur-
ing, attractive and superior economics would certainly be expected to do so. Indeed, the 
PMP industry has recently been challenged to demonstrate the economic advantages of 
its platform, particularly in regard to production scale-up where the relationship between 
capital investment and capacity increase may be distinctly advantageous (Thiel, 00). 
Unfortunately, many published papers and review articles over the years have mislead-
ingly characterized the PMP technology as a “cheap” way to make a protein. There is, of 
course, always a finite cost associated with producing a crop, and with PMPs there can 
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be specific additional costs associated with containment (at least until the plant becomes 
deregulated), particular harvesting practices, etc. Moreover, a complete estimate of cost-of-
production for a plant-derived pharmaceutical cannot be made without data on extraction 
and bioprocessing expenses. For any particular PMP product under consideration, these 
post-harvest details are usually either unknown or based only on experience at small scale. 
Thus, the majority of statements in the literature that proclaim an inherent cheapness 
for PMPs, without justifying that claim, cannot be taken seriously. On the other hand, 
incremental costs associated with PMP scale-up should be appealing, for the simple reason 
that planting more acres in the field, or constructing additional contained facilities such 
as greenhouses, has to be significantly cheaper than building bioreactors for fermenta-
tion. (Bioprocessing expansion costs would likely be very similar for all platforms.) It 
is in this aspect of flexibilty and expansion that the economics of PMPs deserve careful 
consideration.
Most recently the PMP industry has found that its potential pharmaceutical-indus-
try clients are not the only stakeholders needing to be convinced. The potential use of 
food/feed plants as the crop species of choice for some PMP systems has drawn criticism 
from the respective food industry organizations, as well as from environmentalists and 
biotechnology-opposing groups (e.g. see the editorial on page  of Nature Biotechnology 
33, 00, for an overview, and http://www.gmabrands.com/news/docs/Newsrelease.
cfm?docid=09 for an example of food-industry perspective). Concern has been expressed 
over the degree of protection and assurance that could be provided to obviate an envisaged 
possibility of contamination of the food/feed supply with pharmaceutical proteins from 
the PMP variant of the crop, either via genetic means (cross-pollination) or by direct 
mixing of plants or harvested material. Anxiety on this point has generated local/regional 
opposition to one PMP platform that uses a food plant, resulting in that company’s reloca-
tion of its pilot production trials and the resulting loss of a new opportunity for farmers 
at the original site. The fear of food contamination is also reflected in the presently very 
high level of governmental regulation and risk assessment applied to field releases (field 
trials, pilot production) of PMP plants (Peterson and Arntzen, 00). 
Despite these concerns, it has been speculated that PMP crops might fare better than 
most genetically-modified (GM) crops in terms of public perception and acceptance in 
those countries that are uneasy about GM plants in general [for further discussion and 
relevant citations see Einsiedel and Medlock (005)]. The often-heard criticism that 
input traits such as herbicide tolerance do not provide sufficiently obvious benefit for 
the consumer no longer applies, and the product is readily understood as a beneficial 
medicine.
Developing a Dedicated Crop System for PMPs
Concerns about contamination of existing crops with pharmaceutical products coming 
from the corresponding PMP crops would be moot if PMPs were produced using “vehicle” 
species that had hitherto not been developed into crops, i.e. plants that had not previ-
ously been domesticated. However, suitable gene-expression technologies would have to 
be adapted for use with these previously uncultivated species, or developed from scratch, 
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and the domestication aspect alone might take many years. Even with the non-food 
plant, tobacco, there is concern to prevent any possible contamination of the traditional 
crop; the tobacco-production industry in the United States currently has zero tolerance 
for GM contamination.
There is an additional reason to consider the development of a dedicated vehicle plant 
exclusively for PMP applications, namely the lack of desirable characteristics in existing 
crop varieties. Modern crop cultivars are highly customized to the particular applications 
for which they are used. Adaptive enhancements continue to be made through advanced 
breeding and genomics research, improving yield, resistance to pests, and other useful 
traits. Some of these qualities, particularly the more agronomically oriented ones such 
as disease resistance, will still be relevant when the plant is used as a protein-production 
vehicle. However, other traits specific to the PMP application may also be lacking in the 
commonly grown varieties. Examples include productive response and systemic spread 
when infected with virus-based PMP gene vectors, sterility or limited (or late) flowering 
to minimize gene flow via pollen, special morphology and growth habit suited to a specific 
harvesting method that will be used with the PMP application, absence of certain metabo-
lites that may compromise product integrity or quality during bioprocessing, etc. Indeed, 
the design and development of new plant varieties customized for PMP applications is to 
be expected, given the general practice of variety development in crop agriculture.
tobacco is convenient for illustrating vehicle-plant customization. The Nicotiana 
genus contains a large number of species that are found in diverse regions of the world 
and which exhibit a wide range of morphological and other relevant characteristics. Most 
importantly, many of these undomesticated species are already large, bushy and productive 
plants, in contrast to the “wild” relatives of many crop plants, which so often exhibit small, 
low-yielding forms. Moreover, many Nicotiana species have disease-resistance traits not 
found in the traditional, commercial N. tabacum cultivars. Thus, there is an extensive and 
useful germplasm resource, and the domestication breeding path is conveniently short. 
Most of this germplasm has been ignored in breeding traditional tobacco types, presum-
ably because the exotic species and associated variants are unsuited to the manufacture 
of traditional products such as cigarettes. Naturally, these issues have no relevance in the 
new PMP applications of the plant.
table  provides a listing of the most desirable characteristics to be incorporated into 
the new vehicle plant that we are constructing at KtrDC for use with all tobacco-spe-
cific PMP gene-expression technologies. In order to achieve optimal compliance with 
federal regulations concerning limitation of gene flow (genetic “containment”), we have 
adopted a hybridization strategy. Thus the plants set out in the field for production will 
be interspecific hybrids that exhibit a high degree of sterility. One parent of the hybrid 
is an appropriate cultivar of N.	tabacum, whereas the other is a different species of Nico-
tiana. Each parent also contributes different characteristics that are important features 
of the final custom hybrid. For example, for transgenic PMP strategies one parent will 
be expressing the PMP transgene via the appropriate high-level expression system. For 
chloroplast-based expression, this would be the maternal parent. The other parent may 
also be transgenic for other characteristics such as herbicide tolerance, etc.
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It will be noted that the table of characteristics includes economy of production. One 
disadvantage of conventional tobacco for PMP applications is the very high cost of pro-
duction of the traditional crop, resulting from the use of transplants, wide plant spacing, 
and considerable manual labor even pre-harvest. In developing the customized Nicotiana 
hybrids for PMPs, we can also take the opportunity to address the cost-of-production 
issue. For example, mechanized harvesting enables the crop to be produced by sequential 
harvesting and regrowth, unlike traditional tobacco, which is (manually) harvested once. 
This contributes significantly to improved production economics, so productive regrowth 
becomes an important performance trait for the new PMP hybrid lines. 
Along with the development of new hybrid Nicotiana plants, much can be done to 
usefully customize the production practices, further reducing the cost of production for 
PMPs. The mechanized harvesting mentioned above, using plants grown much closer 
together and employing three or four rounds of growth from the same plants over an 
extended growing season, are good examples. Eliminating transplants, and producing the 
crop by direct seeding into the field, would also lower production costs. However, at the 
present time transplanting is actually viewed advantageously relative to direct seeding for 
PMPs, as it further reduces the possibility of volunteer plants’ emerging in the following 
year. Accordingly, we are examining the possibility of achieving more economical raising 
of transplants in the greenhouse, and good progress is being made with higher densities 
of transplant production.
Table 2. deSirable TraiTS and characTeriSTicS of 
a new crop planT cuSTomized for uSe wiTh Tobacco-baSed 
pmp gene-expreSSion TechnologieS.
 Performance traits Production-related traits
 transformable Eonomical production*
 regenerable from cell culture Vigorous regrowth*
 PMP-vector-system compatible Disease resistance
 Sterile Herbicide tolerance
 Identity-preserved Insect resistance
 Desirable metabolite profile High biomass-yield*
 Bioprocessing-optimal Good protein production
  Suited to mechanized harvesting
*Vigorous regrowth (for multiple harvests) and high biomass-yield contribute directly and importantly to eco-
nomical production, but the latter is listed separately as well so as to include improved economy of seedling 
production, transplanting, and many aspects of crop maintenance, as well as economical disposal of waste 
material post-bioprocessing, etc.
We	are	hopeful	that	the	increasing	market	opportunity	(demand)	
and	the	demonstrated	production	capability	(PMP	technology)	
will	soon	converge.
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In Conclusion
The continuing development of protein-based medicines worldwide bodes well for the 
future of the PMP concept. Gene-expression technologies for plant-based production are 
proven and productive. We are hopeful that the increasing market opportunity (demand) 
and the demonstrated production capability (PMP technology) will soon converge to 
achieve large-scale, and ongoing, manufacturing of valuable proteins from one or more 
plant-based platforms. Meanwhile, much can be done to enhance the agricultural inter-
face with PMPs, as I have illustrated above with reference to our work with Nicotiana. 
Existing crops and associated production methods are frequently sub-optimal for ap-
plication to PMPs, but the use of related germplasm that remains compatible with PMP 
gene-expression technologies can not only enhance production economics and facilitate 
regulatory compliance, but also mitigate potential conflict with traditional food and other 
applications of that plant.
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Since 99, Davies has been responsible for designing and overseeing the 
transition of KtrDC from health-related research to its present mission of fa-
cilitating the development of new crops for Kentucky agriculture. The research 
in plant-made pharmaceuticals (PMPs) emphasizes the development of a new, 
PMP-dedicated crop plant and an associated agricultural production system that 
will be useful to all companies using tobacco-based gene-expression technologies 
for protein production. The Center also supports unique research into natural 
products, anticipating that the development of new applications for intrinsic, 
small-molecule plant metabolites will, in turn, create new crop opportunities 
for growers.
